<p>基因編輯股票代表近年生物製藥領域最大的投資趨勢之一。</p>
<p>基因編輯領域採用先進技術編輯不同生物體的 DNA，從而為轉變性治療選擇打開可能性。該領域中最流行的工具是 CRISPR-Cas9，因其在修改 DNA 方面的精準性、速度和成本效益而備受推崇。</p>
<p>然而，對於任何轉變性技術，公司要實現盈虧平衡需要時間。因此，投資基因編輯股票存在風險，但未來可能獲得多倍回報的前景令人難以忽視。投資者的吸引力並不一定在於即時回報，而更在於這些公司承諾的強勁增長潛力。</p>
<p>因此，以熱情和謹慎的態度探索這個高風險領域至關重要。考慮到這一點，以下三家基因編輯股票完全符合要求，提供了可觀的長期增長空間。</p>
<h2>買入的基因編輯股票：CRISPR 治療（CRSP）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：rafapress / Shutterstock.com</p>
<p>瑞士生物科技公司 <strong>CRISPR 治療</strong>（納斯達克股票代碼：<strong>CRSP</strong>）或許是基因編輯平台中最早的倡導者，旨在治療罕見病和常見疾病。儘管公司仍處於無收入階段，但今年情況可能會發生巨大變化。最近，該公司獲得了其治療鐮狀細胞病和依賴輸血型β地中海貧血的突破性 Casgevy 療法的綠燈。因此，分析師預計該公司今年的營收將達到 7.94 億美元，到 2025 年將達到 3.307 億美元。</p>
<p>CRSP 股票雖然表現疲軟，年初至今已經下跌超過 12.8%。這在很大程度上與其自成立以來過去十年未能盈利有關。然而，過去幾年公司經歷了許多事件，走上了全新的軌跡。它正在推進一個有前景的療法管線，針對各種疾病，從血液疾病到癌症和糖尿病，為其帶來了爆炸性增長的機會。</p>
<h2>福泰製藥（VRTX）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：Pavel Kapysh / Shutterstock.com</p>
<p><strong>福泰製藥</strong>（納斯達克股票代碼：<strong>VRTX</strong>）是生物技術領域中最資深的參與者之一。與基因編輯領域的一大批初創公司不同，福泰製藥在製藥領域擁有豐富的歷史，使其能夠利用其龐大的財務資源。</p>
<p>近年來，我們看到它涉足新領域，如基因編輯，針對炎症性和自身免疫性疾病以及某些癌症。此外，它與 CRISPR 治療合作開發 Casgevy 療法，正如前文所述，具有巨大的長期潛力。</p>
<p>福泰製藥的財務狀況非常良好，擁有出色的利潤率和不斷增長的銷售額。令人印象深刻的是，在最近的一個季度，銷售額同比增長了 13.3%。展望 2024 財年，分析師預計該公司的銷售額將達到 107.5 億美元，較上一年增長 16.6%。考慮到這些數據，當前水平下的 VRTX 股票難以忽視。</p>
<h2>Beam Therapeutics（BEAM）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>圖片來源：luchschenF / Shutterstock.com</p>
<p><strong>Beam Therapeutics</strong>（納斯達克股票代碼：<strong>BEAM</strong>）是基因編輯領域的另一家新興初創公司，憑藉其新穎的主要編輯技術結合 CRISPR 技術而引起轟動。其創新方法有助於對基因的特定部分進行精確調整，而不是完全基因替換。因此，該公司仍處於一個充滿巨大潛力的領域的前沿，使其成為一個引人注目的生物製藥前景。</p>
<p>其旗艦藥物 BEAM-302 突顯了主要編輯的有效性，精準地針對嚴重的α-1 抗胰蛋白酶缺乏症（AATD）的直接原因。此外，從財務角度看，Beam 處於穩健地位，最近一個季度以 12 億美元現金結算，預計資金運營將持續到 2027 年。因此，作為該領域新興參與者，Beam 在推動醫學科學邊界的同時，為未來提供巨大的長期增長空間。此外，華爾街對該股給予一致的 “買入” 評級，預計從當前水平上漲 59%。</p>
<p><em>在發佈日期，Muslim Farooque 在本文中提到的證券中沒有（直接或間接）任何頭寸。本文中表達的觀點屬於作者本人，受 InvestorPlace.com 發佈指南約束</em></p>
<p><em>在發佈日期，負責編輯在本文中提到的證券中沒有（直接或間接）任何頭寸</em></p>
<p>Muslim Farooque 是一位熱心的投資者和樂觀主義者。作為一名終身遊戲玩家和科技愛好者，他特別喜歡分析科技股。Muslim 擁有牛津布魯克斯大學應用會計學學士學位。</p>

CRISPR治療

BEAM

福泰制藥

<p>基因編輯股票是生物製藥領域的熱門投資趨勢。CRISPR 治療、福泰製藥和 Beam Therapeutics 是三家提供長期增長潛力的公司。CRISPR 治療正在開發針對各種疾病的治療方案，並預計實現顯著的收入增長。福泰製藥具有強大的財務實力，並與 CRISPR 治療展開合作。Beam Therapeutics 是一家新興初創公司，擁有創新的主編輯技術。這些股票具有高回報潛力，但也伴隨着風險</p>

<p>Gene editing stocks represent one of the biggest investing trends in biopharma in recent years.</p>
<div class="lb-trans"><p>基因編輯股票代表近年生物製藥領域最大的投資趨勢之一。</p>
</div><p>The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options. The most popular tool in the niche is CRISPR-Cas9, which has been touted for its precision, speed, and cost-effectiveness in modifying DNA.</p>
<div class="lb-trans"><p>基因編輯領域採用先進技術編輯不同生物體的 DNA，從而為轉變性治療選擇打開可能性。該領域中最流行的工具是 CRISPR-Cas9，因其在修改 DNA 方面的精準性、速度和成本效益而備受推崇。</p>
</div><p>However, with any transformative technology, breaking even takes time for companies. Therefore, investing in gene editing stocks has its risks, but the prospect of multi-bagger returns down the road is tough to ignore. The lure for investors doesn’t necessarily lie in immediate returns but rather in the robust growth potential these firms promise.</p>
<div class="lb-trans"><p>然而，對於任何轉變性技術，公司要實現盈虧平衡需要時間。因此，投資基因編輯股票存在風險，但未來可能獲得多倍回報的前景令人難以忽視。投資者的吸引力並不一定在於即時回報，而更在於這些公司承諾的強勁增長潛力。</p>
</div><p>Therefore, it’s critical to approach this high-stakes realm with a mix of enthusiasm and caution. With that in mind, these three gene editing stocks fit the bill perfectly, offering substantial long-term upside.</p>
<div class="lb-trans"><p>因此，以熱情和謹慎的態度探索這個高風險領域至關重要。考慮到這一點，以下三家基因編輯股票完全符合要求，提供了可觀的長期增長空間。</p>
</div><h2>Gene Editing Stocks To Buy: Crispr Therapeutics (CRSP)</h2>
<div class="lb-trans"><h2>買入的基因編輯股票：CRISPR 治療（CRSP）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: rafapress / Shutterstock.com</p>
<div class="lb-trans"><p>圖片來源：rafapress / Shutterstock.com</p>
</div><p>Swiss biotech <strong>Crispr Therapeutics</strong>(NASDAQ: <strong>CRSP</strong>) is perhaps the earliest exponent of gene editing platforms, looking to target both rare and common diseases. Though it’s still in the pre-revenue stages, things will likely change dramatically this year. It recently got the green signal for its groundbreaking Casgevy therapy for treating sickle cell disease and transfusion-dependent beta-thalassemia. Consequently, analysts expect the firm to post $79.4 million in revenues this year and a whopping $330.7 million in 2025.</p>
<div class="lb-trans"><p>瑞士生物科技公司 <strong>CRISPR 治療</strong>（納斯達克股票代碼：<strong>CRSP</strong>）或許是基因編輯平台中最早的倡導者，旨在治療罕見病和常見疾病。儘管公司仍處於無收入階段，但今年情況可能會發生巨大變化。最近，該公司獲得了其治療鐮狀細胞病和依賴輸血型β地中海貧血的突破性 Casgevy 療法的綠燈。因此，分析師預計該公司今年的營收將達到 7.94 億美元，到 2025 年將達到 3.307 億美元。</p>
</div><p>CRSP stock, though, has been laggard, having shed more than 12.8% of its value year-to-date (YTD). Much of this is linked to its inability to generate profits over the past decade since its inception. However, the past couple of years have been eventful, with the firm on a completely new trajectory. It’s advancing a promising pipeline of therapies targeting a variety of conditions, from blood diseases to cancer and diabetes, positioning it for explosive growth.</p>
<div class="lb-trans"><p>CRSP 股票雖然表現疲軟，年初至今已經下跌超過 12.8%。這在很大程度上與其自成立以來過去十年未能盈利有關。然而，過去幾年公司經歷了許多事件，走上了全新的軌跡。它正在推進一個有前景的療法管線，針對各種疾病，從血液疾病到癌症和糖尿病，為其帶來了爆炸性增長的機會。</p>
</div><h2>Vertex Pharmaceuticals (VRTX)</h2>
<div class="lb-trans"><h2>福泰製藥（VRTX）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Pavel Kapysh / Shutterstock.com</p>
<div class="lb-trans"><p>圖片來源：Pavel Kapysh / Shutterstock.com</p>
</div><p><strong>Vertex Pharmaceuticals</strong>(NASDAQ: <strong>VRTX</strong>) stands out as one of the most seasoned players in the biotech space. Unlike the sea of start-ups in the gene editing field, Vertex boasts a rich legacy in the pharma space, empowering it to leverage its massive financial resources.</p>
<div class="lb-trans"><p><strong>福泰製藥</strong>（納斯達克股票代碼：<strong>VRTX</strong>）是生物技術領域中最資深的參與者之一。與基因編輯領域的一大批初創公司不同，福泰製藥在製藥領域擁有豐富的歷史，使其能夠利用其龐大的財務資源。</p>
</div><p>In recent years, we’ve seen it dabbling into new areas like gene editing, targeting inflammatory and autoimmune disorders along with certain cancers. Moreover, it collaborated with Crispr Therapeutics on the development of the Casgevy therapy, which holds immense long-term potential as discussed earlier.</p>
<div class="lb-trans"><p>近年來，我們看到它涉足新領域，如基因編輯，針對炎症性和自身免疫性疾病以及某些癌症。此外，它與 CRISPR 治療合作開發 Casgevy 療法，正如前文所述，具有巨大的長期潛力。</p>
</div><p>Vertex’s financials are in excellent shape, backed by a superb margin profile and growing sales. Impressively, in its most recent quarter sales were up a heartening 13.3% year-over-year (YOY). Looking ahead to fiscal 2024, analysts expect the firm to post $10.75 billion in sales, marking a healthy 16.6% jump from the previous year. With these figures in play, VRTX stock is tough to ignore at current levels.</p>
<div class="lb-trans"><p>福泰製藥的財務狀況非常良好，擁有出色的利潤率和不斷增長的銷售額。令人印象深刻的是，在最近的一個季度，銷售額同比增長了 13.3%。展望 2024 財年，分析師預計該公司的銷售額將達到 107.5 億美元，較上一年增長 16.6%。考慮到這些數據，當前水平下的 VRTX 股票難以忽視。</p>
</div><h2>Beam Therapeutics (BEAM)</h2>
<div class="lb-trans"><h2>Beam Therapeutics（BEAM）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: luchschenF / Shutterstock.com</p>
<div class="lb-trans"><p>圖片來源：luchschenF / Shutterstock.com</p>
</div><p><strong>Beam Therapeutics</strong> (NASDAQ: <strong>BEAM</strong>) is another emerging startup in the gene editing arena that’s making waves with its novel prime editing techniques paired with CRISPR technology. Its innovative approach facilitates precise adjustments to specific parts of genes instead of a complete genetic replacement. Hence, the firm remains at the forefront of a sector brimming with tremendous potential, making it a compelling biopharma prospect.</p>
<div class="lb-trans"><p><strong>Beam Therapeutics</strong>（納斯達克股票代碼：<strong>BEAM</strong>）是基因編輯領域的另一家新興初創公司，憑藉其新穎的主要編輯技術結合 CRISPR 技術而引起轟動。其創新方法有助於對基因的特定部分進行精確調整，而不是完全基因替換。因此，該公司仍處於一個充滿巨大潛力的領域的前沿，使其成為一個引人注目的生物製藥前景。</p>
</div><p>Its flagship drug, BEAM-302, underscores the effectiveness of prime editing, targeting the direct cause of severe alpha-1 antitrypsin deficiency (AATD) with incredible precision. Also, from a financial perspective, Beam stands on robust ground, ending its most recent quarter with $1.2 billion in cash, as it projects funding operations through 2027. Hence, as an up-and-coming player in the niche, Beam continues pushing the boundaries of medical science while offering tremendous long-term upside ahead. Moreover, Wall Street assigns a consensus ‘buy’ rating to the stock, forecasting a 59% upside from current levels.</p>
<div class="lb-trans"><p>其旗艦藥物 BEAM-302 突顯了主要編輯的有效性，精準地針對嚴重的α-1 抗胰蛋白酶缺乏症（AATD）的直接原因。此外，從財務角度看，Beam 處於穩健地位，最近一個季度以 12 億美元現金結算，預計資金運營將持續到 2027 年。因此，作為該領域新興參與者，Beam 在推動醫學科學邊界的同時，為未來提供巨大的長期增長空間。此外，華爾街對該股給予一致的 “買入” 評級，預計從當前水平上漲 59%。</p>
</div><p><em>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines</em></p>
<div class="lb-trans"><p><em>在發佈日期，Muslim Farooque 在本文中提到的證券中沒有（直接或間接）任何頭寸。本文中表達的觀點屬於作者本人，受 InvestorPlace.com 發佈指南約束</em></p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or</em></p>
<p><em>indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在發佈日期，負責編輯在本文中提到的證券中沒有（直接或間接）任何頭寸</em></p>
</div><p>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor’s of science degree in applied accounting from Oxford Brookes University.</p>
<div class="lb-trans"><p>Muslim Farooque 是一位熱心的投資者和樂觀主義者。作為一名終身遊戲玩家和科技愛好者，他特別喜歡分析科技股。Muslim 擁有牛津布魯克斯大學應用會計學學士學位。</p>
</div>

3 只基因編輯股票正在塑造醫學的未來